XTalks

AUGUST 17, 2020

chimeric receptor antigen [CAR] T cell) immune modulators (i.e. This typically involves taking T cells from the body, engineering chimeric receptor antigens (CAR) and inserting them into the cells, expanding the cells ex vivo and injecting them back into the body. protein-based biologics) and vaccine treatments.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Drug Discovery World

NOVEMBER 9, 2023

Troy Lionberger, PhD, Senior Vice President, Business Development, Bruker, on: ‘Accelerating functional TCR discovery by phenotyping thousands of live, single T cells in two days’. Chairperson Klampatsa on: ‘Overcoming tumour antigen heterogeneity in the context of car t cell therapy for solid tumours’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 13, 2023

Felix Unverdorben, PhD, Associate Director, Immatics Biotechnologies, on: ‘TCER: Next-generation, half-life extended TCR bispecifics designed to maximise efficacy while minimising toxicities for patients’. Jeremy Fry, Dr, Director of Sales, ProImmune, on: ‘Mastering immunogenicity and biologics development’.

Protein 59

Protein Antibody Engineer Scientist 59